Antibiotics in prevention of skin toxic reactions of epidermal growth factor receptor inhibitors (literature review)

The article is an overview and contains up-to-date information on the use of tetracycline antibiotics in the prevention of acne-like rash in patients receiving therapy with epidermal growth factor receptor inhibitors. According to studies, prevention of skin toxicity is necessary to maintain the effectiveness of the antitumor effect of EGFR inhibitors and to minimize the negative effect of adverse effects from the skin on the quality of life of patients. The use of tetracycline antibiotics in combination with topical therapy and photoprotection for the prevention of acne-like rash against the background of the use of EGFR inhibitors is a fairly safe method for long-term use. Of the antibacterial drugs for the prevention of acne-like rash, the most advisable is the appointment of doxycycline at a dose of 100 mg per day from the first day of taking EGFR inhibitors.

4D-QSAR Analyses for EGFR Inhibitors Based on CDDA-OPS-GA Method

Epidermal growth factor receptor is a preferred target for treating cancer. Compared to 3D-QSAR, 4D-QSAR has the feature of conformational flexibility and free alignment for individual ligands. In present studies, the 4D-QSAR of 131 analogs of 4-anilino quinazoline for EGFR inhibitors was built. The GROMACS package was employed to yield the conformational ensemble profile. The field descriptors of Coulomb and Lennard−Jones potentials were calculated by LQTA-QSAR. The filter descriptors and variable selection is very important, which was performed by means of comparative distribution detection algorithm (CDDA), ordered predictors selection (OPS) and genetic algorithm (GA) method. Best 4D-QSAR model yielded satisfactory statistics (R2 = 0.71), good performance in internal (Q2LOO = 0.60) and external prediction (R2pred = 0.69, k = 0.97, k′ = 1.01). The 4D-QSAR was shown to be robust (Q2LMO = 0.59) and was not built by chance (R2YS = 0.17, Q2YS = −0.25). The model has a good potential for rational design new EGFR inhibitors.